Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Takeda Pharmaceutical Co. Ltd.. (1/5/18). "Press Release: Takeda Announces Intention to Acquire TiGenix. Expands Takeda’s Late Stage Pipeline and Leadership in Gastroenterology". Osaka.

Organisations Organisation Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
  Organisation 2 TiGenix N.V. (Euronext + Nasdaq: TIG)
  Group Takeda (Group)
Products Product darvadstrocel (Cx601)
  Product 2 investment banking
Index term Index term TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share
Persons Person Plump, Andrew (Takeda 201610 CMO + CSO)
  Person 2 Bravo, Eduardo (Nordic Nanovector 201807– CEO before TiGenix + Cellerix + Sanofi-Aventis + SKB)
     


   
Record changed: 2019-06-09

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Takeda (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top